Contribute Try STAT+ Today

A Food and Drug Administration proposal to substitute detailed reviews of new drugs written by specific agency teams with an abbreviated summary is prompting strong protests from academic researchers and public advocates who claim the move is “ill conceived” and will harm public health.

Last June, the FDA issued a notice describing plans to do away with a longstanding practice of posting on its website separate reviews concerning pharmacology, medical chemistry, risk assessment, and biostatistics issues, among other things. These so-called action packages are prepared by individual agency teams as part of their reviews of marketing applications for new medicines.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.